Gateway Investment Advisers LLC Seagen Inc. Transaction History

Gateway Investment Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$191.51 - $216.16 $120,842 - $136,396	631 Added 3.33%	19,595 $4.16 Million
Q2 2023 Jul 13, 2023	SELL	$187.64 - $206.25 $375 - $412	-2 Reduced 0.01%	18,964 $3.65 Million
Q1 2023 Apr 11, 2023	SELL	$127.59 - $203.08 $838,904 - $1.34 Million	-6,575 Reduced 25.74%	18,966 $3.84 Million
Q4 2022 Jan 13, 2023	SELL	$117.37 - $139.17 $785,087 - $930,908	-6,689 Reduced 20.75%	25,541 $0
Q3 2022 Oct 07, 2022	SELL	$135.27 - $180.11 $332,493 - $442,710	-2,458 Reduced 7.09%	32,230 $4.41 Million
Q2 2022 Jul 13, 2022	BUY	$108.81 - $179.33 $327,953 - $540,500	3,014 Added 9.52%	34,688 $6.14 Million
Q1 2022 Apr 14, 2022	BUY	$119.61 - $157.85 $883,917 - $1.17 Million	7,390 Added 30.43%	31,674 $4.56 Million
Q4 2021 Jan 14, 2022	BUY	$142.57 - $190.86 $12,688 - $16,986	89 Added 0.37%	24,284 $3.75 Million
Q3 2021 Oct 22, 2021	BUY	$142.45 - $169.82 $40,598 - $48,398	285 Added 1.19%	24,195 $4.11 Million
Q1 2021 Apr 14, 2021	BUY	$137.51 - $190.8 $5,225 - $7,250	38 Added 0.16%	23,910 $3.32 Million
Q4 2020 Jan 14, 2021	BUY	$164.63 - $211.93 $3.93 Million - $5.06 Million	23,872 New	23,872 $4.18 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Gateway Investment Advisers LLC with notifications on news.